Early Phase Clinical Trial Network. UKMF Spring Day - 13 March 2013. Strategic The most pertinent clinical studies are identified based on Key Objectives and developed and prioritised by a Steering Group of myeloma specialists. Collaborative
Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.
Clinical Trial Network
UKMF Spring Day
- 13 March 2013
The most pertinent clinical studies are identified based on Key Objectives and developed and prioritised by a Steering Group of myeloma specialists.
Stakeholders throughout the NHS, HTA, Patients and the Pharmaceutical Industry work together to implement the most effective clinical trial design and ensure effective adoption of data.
Working as a network, coordinated via a central office with standard processes and procedures and working with NHS and industry stakeholders, the CTN aims to break down the barriers that delay research enabling studies to be delivered quickly and effectively.
Bringing Stakeholders Together
Uni H Wales,
Central Trial Office
8 Core Active
& N Ireland
Improving the setting for adoption of non-commercial data
Making best use of available resources, especially patients
Promote novel clinical trial designs
Supporting novel approaches to licensing e.g. adaptive licensing
Developing novel drug life-cycle strategies
Addressing health economic barriers
Collaboration with pharmaceutical companies
Development of “Pathways Model” to identify future optimum therapy
CTN is part of a wider objective
CTN trials are one part of a wider Myeloma UK objective to impact how clinical trial data is generated and adopted, to more effectively bring optimum treatments to patients.
Individualised treatment based on diagnostic biomarkers (i.e. genetic subgroups)
Individualised treatment based on clinical presentation (clinical subgroups e.g. elderly/frail, high risk)
Access to Treatments
Promoting novel treatments
Identifying evidence gaps for drugs currently in development that may prevent or delay them being approved by NICE and/or taken into UK practice.
Planning studies around expected life-cycle of a drug in real world setting
Strategic Approach to Selecting Trials
CTN trials are identified and prioritised based on two objectives:
Clinical Trial Network
Linking the CTN with Discovery Research
Patients are waiting…
Myeloma patients need more effective treatments with less side-effects.
In order to deliver this in the soonest possible time frame, we have set up
the CTN to be more efficient and more effective.
We must challenge the hurdles and the inefficiencies and strive for
improvements in the system.
Eric Low OBE, CEO Myeloma UK